Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: satety, tolerability and the switch to opal antipsychotic medication in patients with schizophrenia or acute mania

Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: satety, tolerability and the switch to opal antipsychotic medication in patients with schizophrenia or acute mania

Авторы:

Chandrasena R. Dvorakova D. Lee S.I. Mosolov S.N., Osvath P., Pregelj P. Walton R.J., Karagianis J., Treuer T.

Издание:

International Journal of Clinical Practice

Год издания:

2009

Номер:

N 8

Страницы:

1249-1258

Язык:

English

Аннотация:

Background: This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation. Methods: Patients (N = 2011) from 15 countries participated in this prospective, observational, non-interventional study. Inpatients requiring treatment with at least one IM injection of a short-acting antipsychotic were assessed at baseline and within 7 days after the first IM injection. Treatment groups comprised: (i) patients prescribed IM olanzapine at baseline; and (ii) patients prescribed any other IM antipsychotic medication at baseline.

Добавил:

Администратор С.А.Т. 2013-07-20

Ключевые слова:

bipolar disorder, schizophrenia, olanzapine, antipsychotics, психофармакотерапия

Файл:

Скачать файл